SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 9, 1996
COPLEY PHARMACEUTICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
0-20126 04-2514637
(Commission File Number) (IRS Employer Identification No.)
25 John Road
Canton, Massachusetts 02021
(Address of principal executive offices) (Zip Code)
(617) 821-6111
(Registrant's telephone number, including area code)
<PAGE 2>
Item 5. Other Events
On July 9, 1996, Copley Pharmaceutical, Inc. (the "Company") announced
that Kenneth N. Larsen will assume the office of President on an interim
basis in place of Dr. Gabriel R. Cipau, who has resigned all positions in
the Company, as well as a member to the Board of Directors, to pursue other
career interests.
Mr. Larsen has been a member of the Company's Board of Directors since
1989, and currently serves as its Chairman, and also served as a member of
the Board from September 1985 to November 1986. A well-known consultant and
advisor to numerous health-care companies from 1989 to the present, Mr.
Larsen was also a founding member and initial chairman of the Generic
Pharmaceutical Industry Association.
<PAGE 3>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
July 30, 1996
COPLEY PHARMACEUTICAL, INC.
/s/ Kenneth N. Larsen
______________________________
Kenneth N. Larsen
President and Chairman
